89bio logo

89bio

Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases

123 employees · est. 2018 · San Francisco, United States

VS
Synta Pharmaceuticals logo

Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, including cancer and chronic inflammatory diseases.

est. 2000

Synta Pharmaceuticals is the older company (2018 vs 2000).

Side-by-Side Comparison

89bio Synta Pharmaceuticals
Founded
2018 2000 older
Headquarters
San Francisco, United States Not tracked yet
Employees
123 Not tracked yet
Industry
Biopharma, Biotechnology, Pharmaceutical Biotechnology, Health Care, Pharmaceutical
Funding Stage
Post Ipo Equity Post Ipo Equity
Total Funding
$773.20M $217.35M
Funding Rounds
7 8
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical Company, Clinical-stage, FGF21 Analog, NASH Treatment, SHTG Treatment, Liver Diseases, Cardio-metabolic Diseases, Innovative Therapies, Phase 2 Trial, Patient-centric, Ethical Standards, Scientific Advancement, San Francisco, Herzliya, Israel Biopharmaceutical Company, Small Molecule Drugs, Cancer Treatment, Chronic Inflammatory Diseases, Drug Discovery, Clinical Development, Global Partnership, Roche Collaboration, Lead Optimization, Autoimmune Diseases, Hsp90 Inhibitor, Rheumatoid Arthritis, Medical Innovations
Website
89bio.com syntapharma.com
89bio logo

About 89bio

89bio 89bio is a clinical-stage biopharmaceutical company with a focus on developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases. Their lead product candidate, BIO89-100, is an engineered glycoPEGylated analog of FGF21 designed for the treatment...

Synta Pharmaceuticals logo

About Synta Pharmaceuticals

Synta Pharmaceuticals is a biopharmaceutical company founded in 2000, with a focus on discovering, developing, and commercializing small molecule drugs to improve the lives of patients with severe medical conditions such as cancer and chronic inflammatory diseases. The company has a global partnersh...

We will tell you when either one moves

BounceWatch watches 89bio and Synta Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at 89bio and Synta Pharmaceuticals — by email.

Frequently Asked Questions

89bio — Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases. Synta Pharmaceuticals — Innovating patient care with advanced small molecule therapies for severe medical conditions, including cancer and chronic inflammatory diseases.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
89bio has raised $773.20M while Synta Pharmaceuticals has raised $217.35M.
89bio and Synta Pharmaceuticals operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare 89bio with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at 89bio on 9 Jun 2026, and Synta Pharmaceuticals on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy